University of Iowa Research Foundation

Mengshi Li

Michael K Schultz

Dongyoul Lee

Somya Kapoor

Molly Martin

Frances L Johnson

Nicholas Baumhover

Christopher Pigge

Edwin Sagastume

Moustafa Gabr

F Christopher Pigge

F Christoper Pigge

The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I wherein T is a SST2R targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.

Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers

The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I:T-L-X

A method of performing a chelating reaction comprising contacting a divalent metal with a compound of Formula (I): or a salt thereof wherein: each of R-Ris independently selected from the group consisting of CHCOORand CHC(═O)NHR; each of R-Ris independently selected from the group consisting of H and -L-X; each Ra is independently selected from the group consisting of H and -L-X; each L is independently selected from the group consisting of absent and a linking group; and each X is a biological agent; and wherein the contacting occurs at a temperature below about 40° C. to form a chelated composition.

Compositions for chelating metals at low temperatures

The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I:T-L-Xwherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.

Compositions and methods of treating melanoma

The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).

Growing community of inventors

Iowa City, IA, United States of America

Mengshi Li